Updated recommendations for HER2 testing in the UK

I. O. Ellis, J. Bartlett, M. Dowsett, S. Humphreys, B. Jasani, K. Miller, S. E. Pinder, A. Rhodes, R. Walker

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of advanced breast cancer in the UK. Emphasis is placed on the standardisation of methodology and assessment and strategies to achieve high quality performance. A two phase testing algorithm based on first line immunocytochemistry evaluation and second line fluorescence in situ hybridisation assessment of borderline cases is recommended. To ensure maintenance of expertise, an annual caseload volume of at least 250 cases is recommended for laboratories providing a testing service.

Original languageEnglish
Pages (from-to)233-237
Number of pages5
JournalJournal of Clinical Pathology
Volume57
Issue number3
DOIs
Publication statusPublished - Mar 2004
Externally publishedYes

Fingerprint

Fluorescence In Situ Hybridization
Immunohistochemistry
Maintenance
Breast Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Ellis, I. O., Bartlett, J., Dowsett, M., Humphreys, S., Jasani, B., Miller, K., ... Walker, R. (2004). Updated recommendations for HER2 testing in the UK. Journal of Clinical Pathology, 57(3), 233-237. https://doi.org/10.1136/jcp.2003.007724

Updated recommendations for HER2 testing in the UK. / Ellis, I. O.; Bartlett, J.; Dowsett, M.; Humphreys, S.; Jasani, B.; Miller, K.; Pinder, S. E.; Rhodes, A.; Walker, R.

In: Journal of Clinical Pathology, Vol. 57, No. 3, 03.2004, p. 233-237.

Research output: Contribution to journalArticle

Ellis, IO, Bartlett, J, Dowsett, M, Humphreys, S, Jasani, B, Miller, K, Pinder, SE, Rhodes, A & Walker, R 2004, 'Updated recommendations for HER2 testing in the UK', Journal of Clinical Pathology, vol. 57, no. 3, pp. 233-237. https://doi.org/10.1136/jcp.2003.007724
Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K et al. Updated recommendations for HER2 testing in the UK. Journal of Clinical Pathology. 2004 Mar;57(3):233-237. https://doi.org/10.1136/jcp.2003.007724
Ellis, I. O. ; Bartlett, J. ; Dowsett, M. ; Humphreys, S. ; Jasani, B. ; Miller, K. ; Pinder, S. E. ; Rhodes, A. ; Walker, R. / Updated recommendations for HER2 testing in the UK. In: Journal of Clinical Pathology. 2004 ; Vol. 57, No. 3. pp. 233-237.
@article{a57f0028dc384a468886e7374ecf4b89,
title = "Updated recommendations for HER2 testing in the UK",
abstract = "This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of advanced breast cancer in the UK. Emphasis is placed on the standardisation of methodology and assessment and strategies to achieve high quality performance. A two phase testing algorithm based on first line immunocytochemistry evaluation and second line fluorescence in situ hybridisation assessment of borderline cases is recommended. To ensure maintenance of expertise, an annual caseload volume of at least 250 cases is recommended for laboratories providing a testing service.",
author = "Ellis, {I. O.} and J. Bartlett and M. Dowsett and S. Humphreys and B. Jasani and K. Miller and Pinder, {S. E.} and A. Rhodes and R. Walker",
year = "2004",
month = "3",
doi = "10.1136/jcp.2003.007724",
language = "English",
volume = "57",
pages = "233--237",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Updated recommendations for HER2 testing in the UK

AU - Ellis, I. O.

AU - Bartlett, J.

AU - Dowsett, M.

AU - Humphreys, S.

AU - Jasani, B.

AU - Miller, K.

AU - Pinder, S. E.

AU - Rhodes, A.

AU - Walker, R.

PY - 2004/3

Y1 - 2004/3

N2 - This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of advanced breast cancer in the UK. Emphasis is placed on the standardisation of methodology and assessment and strategies to achieve high quality performance. A two phase testing algorithm based on first line immunocytochemistry evaluation and second line fluorescence in situ hybridisation assessment of borderline cases is recommended. To ensure maintenance of expertise, an annual caseload volume of at least 250 cases is recommended for laboratories providing a testing service.

AB - This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of advanced breast cancer in the UK. Emphasis is placed on the standardisation of methodology and assessment and strategies to achieve high quality performance. A two phase testing algorithm based on first line immunocytochemistry evaluation and second line fluorescence in situ hybridisation assessment of borderline cases is recommended. To ensure maintenance of expertise, an annual caseload volume of at least 250 cases is recommended for laboratories providing a testing service.

UR - http://www.scopus.com/inward/record.url?scp=1542511907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542511907&partnerID=8YFLogxK

U2 - 10.1136/jcp.2003.007724

DO - 10.1136/jcp.2003.007724

M3 - Article

VL - 57

SP - 233

EP - 237

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 3

ER -